Dabigatran versus Warfarin in Patients with Atrial FibrillationStuart J. Connolly, Lars Wallentin, Michael D. Ezekowitz et al.|New England Journal of Medicine|2009Cited by 11.2k
Alirocumab and Cardiovascular Outcomes after Acute Coronary SyndromeGregory G. Schwartz, Andreas M. Zeiher, Philippe Gabríel Steg et al.|New England Journal of Medicine|2018Cited by 3.5k
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary SyndromeMarc A. Pfeffer, Jean‐Claude Tardif, Brian Claggett et al.|New England Journal of Medicine|2015Cited by 2.3k
Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort studySalim Yusuf, Gilles R. Dagenais, Khalid Yusoff et al.|The Lancet|2019Cited by 2k
Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) TrialMarc A. Pfeffer, Bertram Pitt, Brian Claggett et al.|Circulation|2014Cited by 1k